Tag: Biopharmaceutical Development

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

Thermo Fisher Scientific has gone on to announce quite a major expansion of its Bioprocess Design Centers in Asia, hence deepening its investment within...

IQVIA, known across the life sciences industry for its clinical research operations, commercial analytics, and health-data expertise, has entered a strategic collaboration with Amazon...

Regeneron Pharmaceuticals is going ahead and investing more funds into gene editing, as it has announced a collaboration with Tessera Therapeutics in December 2025,...

Azerbaijan and Jordan are looking out for new opportunities in order to establish a joint pharmaceutical venture, thereby signalling a very robust step towards...

The FDA has gone on to propose certain new policies in order to accelerate biosimilar drug development and at the same time also lower...